ScreenerHero

LABTLakewood-Amedex Biotherapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · lakewoodamedex.com
2.240USD0.00%Mkt Cap: 5.31M $P/E: —

Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap5.31M $
Enterprise Value706.51K $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-3.85M $
Revenue/Share—
Last Price2.240 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.10
EV/Revenue—
P/S—
P/B1.10
EPS (TTM)-3.19
EPS (Forward)—
52W Range
1.6601% of range98.20
52W High98.20 USD
52W Low1.660 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE195.85%
ROA-798.93%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.94M $
CapEx (TTM)—
FCF Margin—
FCF Yield-17.17%
Net Debt-4.48M $
Net Debt/EBITDA0.62
Balance Sheet
Debt/Equity-0.85
Current Ratio7.70
Quick Ratio7.29
Book Value/Sh1.997 USD
Cash/Share1.935 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJun 22, 2026
Analyst Consensus
Rating—
Target (Mean)12.00 USD
Upside (mean)+435.7%
Target Range12.00 USD – 12.00 USD
# Analysts1
Ownership
Shares Out.2.37M
Float913.85K
Insiders37.13%
Institutions4.19%
Short Interest
Short Ratio0.0d
Short % Float21.01%
Short % Out.7.20%
Shares Short126.08K
Short (prev mo.)37.77K
Technical
SMA 503.148 (-28.8%)
SMA 20010.74 (-79.1%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)2.85M
Avg Vol (10d)105.14K
Technical Indicators
RSI (14)35.0
MACD-0.4371
MACD Signal-0.6193
MACD Hist.+0.1822
BB Upper2.502 USD
BB Middle2.224 USD
BB Lower1.945 USD
BB Width25.05%
ATR (14)0.4256 USD
Vol Ratio (20d)0.44x